Effective date
Medicare changes effective February 5, 2026
18 CMS and MAC policy updates take effect on this date. Every entry links to the government document it came from.
CMS Coverage API · 18
- LCD L36335: MolDX: NRAS Genetic Testing — Noridian
LCD-L36335NoridianOncologysource ↗
- LCD L39001: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing — Noridian
LCD-L39001NoridianInfectious Disease / Microbiologysource ↗
- LCD L35160: MolDX: Molecular Diagnostic Tests (MDT) — Noridian
LCD-L35160NoridianClinical Laboratorysource ↗
- LCD L39948: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — Noridian
LCD-L39948NoridianGenetic Testingsource ↗
- LCD L39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
LCD-L39923NoridianHematologysource ↗
- LCD L39682: MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules — Noridian
LCD-L39682NoridianEndocrinologysource ↗
- LCD L39230: MolDX: Plasma-Based Genomic Profiling in Solid Tumors — Noridian
LCD-L39230NoridianOncologysource ↗
- LCD L38643: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells — Noridian
LCD-L38643NoridianOncologysource ↗
- LCD L38327: MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer — Noridian
LCD-L38327NoridianOncologysource ↗
- LCD L38151: MolDX: Pigmented Lesion Assay — Noridian
LCD-L38151NoridianDermatologysource ↗
- LCD L38123: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian
LCD-L38123NoridianOncologysource ↗
- LCD L38119: MolDX: Next-Generation Sequencing for Solid Tumors — Noridian
LCD-L38119NoridianOncologysource ↗
- LCD L36941: MolDX: Oncotype DX® Breast Cancer for DCIS (Genomic Health™) — Noridian
LCD-L36941NoridianOncologysource ↗
- LCD L38351: MolDX: Repeat Germline Testing — Noridian
LCD-L38351NoridianOncologysource ↗
- LCD L37299: MolDX: Prometheus® IBD sgi Diagnostic® Policy — Noridian
LCD-L37299NoridianGastroenterologysource ↗
- LCD L38339: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease — Noridian
LCD-L38339NoridianOncologysource ↗
- LCD L38814: MolDX: Minimal Residual Disease Testing for Cancer — Noridian
LCD-L38814NoridianOncologysource ↗
- LCD L38972: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer — Noridian
LCD-L38972NoridianOncologysource ↗